Gujarat Kidney And Super Speciality Limited (GKSL)
Small CapPharma stocks · Small cap · NSE
Gujarat Kidney And Super Speciality Limited operates in Hospitals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is acceptable, price trend is neutral, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Bad · 2/100PAT -1% YoY · margin compression · Rev +125% YoY · +12% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹34.3 Cr | +124.7% | +12.1% |
| EBITDA | ₹8.4 Cr | -2.9% | +32.9% |
| Operating margin | 24.4% | -3208 bps | +381 bps |
| PAT | ₹5.3 Cr | -1.5% | +10.4% |
| PAT margin | 15.5% | -1988 bps | -25 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Issuer presentation review pending
Gujarat Kidney And Super Speciality Limited operates in Hospitals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
Trend score and candlestick chart
60BullishSMA20 +17.7% / mo · RSI overbought · MACD + · near 52W high · sector +2.2pp vs Nifty (3M)
Technical chart
GKSLdaily · 1Y · AUTO+58.7%Daily history is available from 2025-12-30; the requested 1Y window is partially covered.
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 83. Wait for confirmation.
- SMA20 rising (~15.0% over last month) — short-term momentum positive.
- RSI(14) at 83 — overbought zone; risk of mean reversion.
- MACD above signal, histogram expanding — bullish momentum building.
- Within 3% of 52-week high — testing resistance.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 35 · WATCHLIST · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 35 · WATCHLIST · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Growth contributes 23/25 to the score.
- Balance sheet contributes 10/15 to the score.
- Valuation contributes 0/30 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -79.4%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -1 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 35th percentile of the scored universe and 25th percentile within Pharma. Main check: cash conversion is weak at 28/100.
Healthy Trust Lite: Promoter holding is 71.5%. Key concern: Operating cash flow is negative at ₹-4 Cr.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 25th pctile, median 70 · Small: 40th pctile, median 66
10 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 71.5%.
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Operating cash flow is negative at ₹-4 Cr.
- ▸Only 1 years of positive FCF.
- ▸ROCE trend is -13.8%.
- ▸OPM spread across recent quarters is 35.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 86.10
- P/B
- 5.41
- EV/EBITDA
- 43.47
- Market Cap
- 1362.00Cr
Profitability
- ROE
- 11.10%
- ROCE
- 14.50%
- ROA
- 5.70%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- —
- EPS 5Y
- 104.08%
- Revenue 3Y
- 1058.00%
- EPS 3Y
- 260.20%
Balance Sheet
- Debt/Equity
- 0.11
- Interest Coverage
- 13.50×
- Altman Z
- 8.06
- Book Value
- 32.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- -4.00 Cr
- EPS TTM
- 2.14
Shareholding
- Promoter Hold
- 71.45%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 97%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.